What is AIM Trials?
Headquartered in Plano and Dallas, AIM Trials operates as a specialized clinical research organization dedicated to the intersection of mental health and general medicine. The firm manages a diverse portfolio of studies, ranging from pediatric autism research to adult depression and irritable bowel syndrome treatments. By bridging the gap between innovative pharmaceutical development and patient care, AIM Trials provides essential research services to sponsors, ensuring that data integrity and participant safety remain at the forefront of every clinical study. Their market position is defined by a dual focus on high-quality data collection and the facilitation of access to emerging medical therapies.
How much funding has AIM Trials raised?
AIM Trials has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in AIM Trials
PPP
Public-Private Partnership
What's next for AIM Trials?
Following this late-stage financing, AIM Trials is expected to prioritize the expansion of its clinical trial capacity and the enhancement of its research service offerings. The strategic deployment of this capital will likely focus on scaling operational efficiencies within their Dallas-Plano network, allowing the firm to accommodate a higher volume of complex medical studies. As the organization matures, the focus will shift toward integrating advanced data analytics to streamline trial timelines, thereby solidifying its reputation as a reliable partner for healthcare sponsors seeking to accelerate the path to regulatory approval for new medical treatments.
See full AIM Trials company page
